BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells

Mark Wroblewski, Marina Scheller-Wendorff, Florian Udonta, Raimund Bauer, Jara Schlichting, Lin Zhao, Isabel Ben Batalla, Victoria Gensch, Sarina Päsler, Lei Wu, Marek Wanior, Hanna Taipaleenmäki, Simona Bolamperti, Zeynab Najafova, Klaus Pantel, Carsten Bokemeyer, Jun Qi, Eric Hesse, Stefan Knapp, Steven JohnsenSonja Loges

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Although inhibitors of bromodomain and extra terminal domain (BET) proteins show promising clinical activity in different hematologic malignancies, a systematic analysis of the consequences of pharmacological BET inhibition on healthy hematopoietic (stem) cells is urgently needed. We found that JQ1 treatment decreases the numbers of pre-, immature and mature B cells while numbers of early pro-B cells remain constant. In addition, JQ1 treatment increases apoptosis in T cells, all together leading to reduced cellularity in thymus, bone marrow and spleen. Furthermore, JQ1 induces proliferation of long-term hematopoietic stem cells, thereby increasing stem cell numbers. Due to increased numbers, JQ1-treated hematopoietic stem cells engrafted better after stem cell transplantation and repopulated the hematopoietic system significantly faster after sublethal myeloablation. As quantity and functionality of hematopoietic stem cells determine the duration of life-threatening myelosuppression, BET inhibition might benefit patients in myelosuppressive conditions.

Original languageEnglish (US)
Pages (from-to)939-948
Number of pages10
JournalHaematologica
Volume103
Issue number6
DOIs
StatePublished - Jun 3 2018
Externally publishedYes

Fingerprint

Hematopoietic Stem Cells
B-Lymphoid Precursor Cells
Cell Count
Hematopoietic System
Stem Cell Transplantation
Hematologic Neoplasms
Thymus Gland
Stem Cells
Spleen
Bone Marrow
Pharmacology
Apoptosis
T-Lymphocytes
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Wroblewski, M., Scheller-Wendorff, M., Udonta, F., Bauer, R., Schlichting, J., Zhao, L., ... Loges, S. (2018). BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells. Haematologica, 103(6), 939-948. https://doi.org/10.3324/haematol.2017.181354

BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells. / Wroblewski, Mark; Scheller-Wendorff, Marina; Udonta, Florian; Bauer, Raimund; Schlichting, Jara; Zhao, Lin; Batalla, Isabel Ben; Gensch, Victoria; Päsler, Sarina; Wu, Lei; Wanior, Marek; Taipaleenmäki, Hanna; Bolamperti, Simona; Najafova, Zeynab; Pantel, Klaus; Bokemeyer, Carsten; Qi, Jun; Hesse, Eric; Knapp, Stefan; Johnsen, Steven; Loges, Sonja.

In: Haematologica, Vol. 103, No. 6, 03.06.2018, p. 939-948.

Research output: Contribution to journalArticle

Wroblewski, M, Scheller-Wendorff, M, Udonta, F, Bauer, R, Schlichting, J, Zhao, L, Batalla, IB, Gensch, V, Päsler, S, Wu, L, Wanior, M, Taipaleenmäki, H, Bolamperti, S, Najafova, Z, Pantel, K, Bokemeyer, C, Qi, J, Hesse, E, Knapp, S, Johnsen, S & Loges, S 2018, 'BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells', Haematologica, vol. 103, no. 6, pp. 939-948. https://doi.org/10.3324/haematol.2017.181354
Wroblewski M, Scheller-Wendorff M, Udonta F, Bauer R, Schlichting J, Zhao L et al. BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells. Haematologica. 2018 Jun 3;103(6):939-948. https://doi.org/10.3324/haematol.2017.181354
Wroblewski, Mark ; Scheller-Wendorff, Marina ; Udonta, Florian ; Bauer, Raimund ; Schlichting, Jara ; Zhao, Lin ; Batalla, Isabel Ben ; Gensch, Victoria ; Päsler, Sarina ; Wu, Lei ; Wanior, Marek ; Taipaleenmäki, Hanna ; Bolamperti, Simona ; Najafova, Zeynab ; Pantel, Klaus ; Bokemeyer, Carsten ; Qi, Jun ; Hesse, Eric ; Knapp, Stefan ; Johnsen, Steven ; Loges, Sonja. / BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells. In: Haematologica. 2018 ; Vol. 103, No. 6. pp. 939-948.
@article{74ce6432292c41d2b6591fd9cb89b578,
title = "BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells",
abstract = "Although inhibitors of bromodomain and extra terminal domain (BET) proteins show promising clinical activity in different hematologic malignancies, a systematic analysis of the consequences of pharmacological BET inhibition on healthy hematopoietic (stem) cells is urgently needed. We found that JQ1 treatment decreases the numbers of pre-, immature and mature B cells while numbers of early pro-B cells remain constant. In addition, JQ1 treatment increases apoptosis in T cells, all together leading to reduced cellularity in thymus, bone marrow and spleen. Furthermore, JQ1 induces proliferation of long-term hematopoietic stem cells, thereby increasing stem cell numbers. Due to increased numbers, JQ1-treated hematopoietic stem cells engrafted better after stem cell transplantation and repopulated the hematopoietic system significantly faster after sublethal myeloablation. As quantity and functionality of hematopoietic stem cells determine the duration of life-threatening myelosuppression, BET inhibition might benefit patients in myelosuppressive conditions.",
author = "Mark Wroblewski and Marina Scheller-Wendorff and Florian Udonta and Raimund Bauer and Jara Schlichting and Lin Zhao and Batalla, {Isabel Ben} and Victoria Gensch and Sarina P{\"a}sler and Lei Wu and Marek Wanior and Hanna Taipaleenm{\"a}ki and Simona Bolamperti and Zeynab Najafova and Klaus Pantel and Carsten Bokemeyer and Jun Qi and Eric Hesse and Stefan Knapp and Steven Johnsen and Sonja Loges",
year = "2018",
month = "6",
day = "3",
doi = "10.3324/haematol.2017.181354",
language = "English (US)",
volume = "103",
pages = "939--948",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "6",

}

TY - JOUR

T1 - BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells

AU - Wroblewski, Mark

AU - Scheller-Wendorff, Marina

AU - Udonta, Florian

AU - Bauer, Raimund

AU - Schlichting, Jara

AU - Zhao, Lin

AU - Batalla, Isabel Ben

AU - Gensch, Victoria

AU - Päsler, Sarina

AU - Wu, Lei

AU - Wanior, Marek

AU - Taipaleenmäki, Hanna

AU - Bolamperti, Simona

AU - Najafova, Zeynab

AU - Pantel, Klaus

AU - Bokemeyer, Carsten

AU - Qi, Jun

AU - Hesse, Eric

AU - Knapp, Stefan

AU - Johnsen, Steven

AU - Loges, Sonja

PY - 2018/6/3

Y1 - 2018/6/3

N2 - Although inhibitors of bromodomain and extra terminal domain (BET) proteins show promising clinical activity in different hematologic malignancies, a systematic analysis of the consequences of pharmacological BET inhibition on healthy hematopoietic (stem) cells is urgently needed. We found that JQ1 treatment decreases the numbers of pre-, immature and mature B cells while numbers of early pro-B cells remain constant. In addition, JQ1 treatment increases apoptosis in T cells, all together leading to reduced cellularity in thymus, bone marrow and spleen. Furthermore, JQ1 induces proliferation of long-term hematopoietic stem cells, thereby increasing stem cell numbers. Due to increased numbers, JQ1-treated hematopoietic stem cells engrafted better after stem cell transplantation and repopulated the hematopoietic system significantly faster after sublethal myeloablation. As quantity and functionality of hematopoietic stem cells determine the duration of life-threatening myelosuppression, BET inhibition might benefit patients in myelosuppressive conditions.

AB - Although inhibitors of bromodomain and extra terminal domain (BET) proteins show promising clinical activity in different hematologic malignancies, a systematic analysis of the consequences of pharmacological BET inhibition on healthy hematopoietic (stem) cells is urgently needed. We found that JQ1 treatment decreases the numbers of pre-, immature and mature B cells while numbers of early pro-B cells remain constant. In addition, JQ1 treatment increases apoptosis in T cells, all together leading to reduced cellularity in thymus, bone marrow and spleen. Furthermore, JQ1 induces proliferation of long-term hematopoietic stem cells, thereby increasing stem cell numbers. Due to increased numbers, JQ1-treated hematopoietic stem cells engrafted better after stem cell transplantation and repopulated the hematopoietic system significantly faster after sublethal myeloablation. As quantity and functionality of hematopoietic stem cells determine the duration of life-threatening myelosuppression, BET inhibition might benefit patients in myelosuppressive conditions.

UR - http://www.scopus.com/inward/record.url?scp=85048056367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048056367&partnerID=8YFLogxK

U2 - 10.3324/haematol.2017.181354

DO - 10.3324/haematol.2017.181354

M3 - Article

C2 - 29567778

AN - SCOPUS:85048056367

VL - 103

SP - 939

EP - 948

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 6

ER -